| 1 | Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. (Hayes FA, Green AA, Casper J, Cornet J, Evans WE) Cancer 1981 Oct 15;48(8):1715-8 93 Citations |
| 1 | Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide. (Chen G, Pan QC) Cancer Chemother Pharmacol 1988;22(4):303-7 37 Citations |
| 1 | Cisplatin and myoelectric activity. (Lang IM) Dig Dis Sci 1988 Oct;33(10):1342-3 |
| 1 | Determination of intracellular reduced glutathione and glutathione related enzyme activities in cisplatin-sensitive and resistant experimental ovarian carcinoma cell lines. (Chen G, Frei E, Zeller WJ) Cancer Lett 1989 Aug;46(3):207-11 22 Citations |
| 1 | Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo. (Chen G, Zeller WJ) Cancer Chemother Pharmacol 1990;26(1):37-41 20 Citations |
| 1 | In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line. (Chen G, Zeller WJ) J Cancer Res Clin Oncol 1990;116(5):443-7 23 Citations |
| 1 | Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. (McCroskey RD, Mosher DF, Spencer CD, Prendergast E, Longo WL) Cancer 1990 Jul 15;66(2):246-50 39 Citations |
| 1 | Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumour cell line. (Chen G, Hutter KJ, Bullerdiek J, Zeller WJ) J Cancer Res Clin Oncol 1991;117(6):539-42 10 Citations |
| 1 | Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. (Chen G, Zeller WJ) Anticancer Res 1991;11(6):2231-7 26 Citations |
| 1 | Investigations on synergistic effects of BSO and 3AB for the reversal of cisplatin resistance (Chen G, Zeller WJ) Tumor Diagnostik Und Therapie 1991;12(6):226-229 2 Citations |
| 1 | Antitumor activity of thaliblastine (NSC-68075) in experimental ovarian tumor cell lines sensitive and resistant to cisplatin. (Chen G, Todorov DK, Zeller WJ) Cancer Lett 1992 Feb 29;62(2):173-7 14 Citations |
| 1 | Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and -resistant rat ovarian tumor cell lines. (Chen G, Zeller WJ) Cancer Lett 1992 Oct 30;67(1):27-33 10 Citations |
| 1 | Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin. (Chen G, Zeller WJ) Anticancer Res 1993;13(1):219-23 5 Citations |
| 1 | Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo. (Chen G, Zeller WJ) Cancer Chemother Pharmacol 1993;33(2):157-62 16 Citations |
| 1 | Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. (Bürkle A, Chen G, Küpper JH, Grube K, Zeller WJ) Carcinogenesis 1993 Apr;14(4):559-61 99 Citations |
| 1 | Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin. (Chen G, Zeller WJ, Todorov DK) Anticancer Res 1993;13(5A):1269-75 10 Citations |
| 1 | Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells. (Chen G, Zeller WJ) Anticancer Res 1994;14(4A):1461-7 8 Citations |
| 1 | Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells. (Assem M, Bonvalot S, Beltramo JL, Garrido C, Dimanche-Boitrel MT, Genne P, Rebibou JM, Caillot D, Chauffert B) Br J Cancer 1994 Oct;70(4):631-5 22 Citations |
| 1 | Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. (Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen MB, Williams RD) J Urol 1994 Dec;152(6 Pt 2):2272-5 38 Citations |
| 1 | Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas (Jones DV, Sugarman SM, Markowitz AB, Levin B, Abbruzzese JL, Evans DB, Charnsangavej C, Smith R, Patt YZ) Oncology Reports 1995;2(6):1121-1123 |
| 1 | Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy. (Dejager D, Redlich PN, Dayer AM, Davis HL, Komorowski RA) J Surg Oncol 1995 Jul;59(3):199-203 70 Citations |
| 1 | Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. (Chen G, Hutter KJ, Zeller WJ) Cell Biol Toxicol 1995 Oct;11(5):273-81 28 Citations |
| 1 | Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells. (Khoshyomn S, Manske GC, Lew SM, Wald SL, Penar PL) Pediatr Neurosurg 2000 Sep;33(3):123-31 38 Citations |
| 1 | High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. (Regine WF, Valentino J, Arnold SM, Haydon RC, Sloan D, Kenady D, Strottmann J, Pulmano C, Mohiuddin M) J Clin Oncol 2001 Jul 15;19(14):3333-9 31 Citations |
| 1 | Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. (Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M, Benda J) J Clin Oncol 2002 Apr 01;20(7):1832-7 124 Citations |
| 1 | Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates. (Baruah H, Rector CL, Monnier SM, Bierbach U) Biochem Pharmacol 2002 Jul 15;64(2):191-200 88 Citations |
| 1 | A phase II study of concomitant hyperfractionated radiation therapy and double dose intra-arterial cisplatin for squamous cell carcinoma of the head and neck. (Regine WF, Valentino J, Arnold SM, Sloan D, Kenady D, Strottmann J, Mohiuddin M) Technol Cancer Res Treat 2002 Apr;1(2):133-40 2 Citations |
| 1 | Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. (Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G) Cancer 2004 Apr 15;100(8):1639-45 176 Citations |
| 1 | Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. (Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H) J Clin Oncol 2005 Mar 20;23(9):2004-11 673 Citations |
| 1 | Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. (Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D) J Clin Oncol 2006 Feb 01;24(4):663-7 93 Citations |
| 1 | Re: Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion, by Muraoka M, Oka T, Akamine S, et al. (Johnstone DW) J Surg Oncol 2006 Mar 15;93(4):255-6 |
| 1 | Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. (Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA) Cancer 2007 Jan 01;109(1):33-40 55 Citations |
| 1 | Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. (Small W Jr, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, Erickson B, Jhingran A, Greven K) Int J Radiat Oncol Biol Phys 2007 Jul 15;68(4):1081-7 129 Citations |
| 1 | Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. (Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K) J Clin Oncol 2007 Oct 20;25(30):4800-5 319 Citations |
| 1 | Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. (Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB) J Clin Oncol 2008 Jul 20;26(21):3487-95 438 Citations |
| 1 | Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer? (Pisters PW, Evans DB) Ann Surg 2008 Aug;248(2):152-3 4 Citations |
| 1 | Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. (Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC) Int J Radiat Oncol Biol Phys 2009 Mar 01;73(3):779-88 107 Citations |
| 1 | Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. (Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS, Rader JS) Gynecol Oncol 2009 Mar;112(3):553-7 16 Citations |
| 1 | Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. (Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, Garden AS, Kuettel MR, Sidhu K, Schultz CJ, Trotti A, Ang KK) J Clin Oncol 2009 Oct 01;27(28):4727-32 35 Citations |
| 1 | Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. (Nugent EK, Case AS, Hoff JT, Zighelboim I, DeWitt LL, Trinkhaus K, Mutch DG, Thaker PH, Massad LS, Rader JS) Gynecol Oncol 2010 Mar;116(3):438-41 63 Citations |
| 2 | Induction of apoptosis with cisplatin enhances calcium oxalate crystal adherence to inner medullary collecting duct cells. (Kleinman JG, Sorokina EA, Wesson JA) Urol Res 2010 Apr;38(2):97-104 11 Citations |
| 1 | Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. (Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R) Cancer Chemother Pharmacol 2010 Nov;66(6):1087-93 17 Citations |
| 1 | Corrigendum to "Chemoradiation in locally advanced cervical carcinoma: An analysis of cisplatin dosing and other clinical prognostic factors" [Gynecol. Oncol. 116 (2010) 438-441] (DOI:10.1016/j.ygyno.2009.09.045) (Nugent EK, Case AS, Hoff JT, Zighelboim I, DeWitt LL, Trinkhaus K, Mutch DG, Thaker PH, Massad LS, Rader JS) Gynecologic Oncology July 2010;118(1):99 |
| 2 | Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. (Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D, Olthoff K, Christians K, Pappas S, Rilling W, Soulen MC) Cancer 2011 Apr 01;117(7):1498-505 152 Citations |
| 1 | Regulation of glycosyltransferase genes in apoptotic breast cancer cells induced by L: -PPMP and cisplatin. (Ma R, Hopp EA, Decker NM, Loucks A, Johnson JR, Moskal J, Basu M, Banerjee S, Basu S) Adv Exp Med Biol 2011;705:621-42 4 Citations |
| 1 | Cisplatin ototoxicity affecting cochlear implant benefit. (Harris MS, Gilbert JL, Lormore KA, Musunuru SA, Fritsch MH) Otol Neurotol 2011 Aug;32(6):969-72 12 Citations |
| 1 | Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116. (Small W Jr, Winter K, Levenback C, Iyer R, Hymes SR, Jhingran A, Gaffney D, Erickson B, Greven K) Int J Gynecol Cancer 2011 Oct;21(7):1266-75 40 Citations |
| 2 | Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. (Mukhopadhyay P, Horváth B, Zsengellér Z, Zielonka J, Tanchian G, Holovac E, Kechrid M, Patel V, Stillman IE, Parikh SM, Joseph J, Kalyanaraman B, Pacher P) Free Radic Biol Med 2012 Jan 15;52(2):497-506 192 Citations |
| 1 | Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. (Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J) Pediatr Blood Cancer 2012 Jul 15;59(1):144-8 136 Citations |
| 1 | Cisplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity. (Zsengellér ZK, Ellezian L, Brown D, Horváth B, Mukhopadhyay P, Kalyanaraman B, Parikh SM, Karumanchi SA, Stillman IE, Pacher P) J Histochem Cytochem 2012 Jul;60(7):521-9 109 Citations |
| 1 | Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy. (Johnson A, Tarima S, Wong S, Friedland DR, Runge CL) JAMA Otolaryngol Head Neck Surg 2013 Mar;139(3):256-64 15 Citations |
| 1 | Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. (Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Alvarez Secord A, Lippmann LT, Dehdashti F, Rader JS) Gynecol Oncol 2013 Jul;130(1):64-8 79 Citations |
| 1 | Commentary on "Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?" Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108-13 [Epub 2012 Aug 15]. (See WA) Urol Oncol 2013 Jul;31(5):716-7 2 Citations |
| 1 | Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation. (Kulhari H, Pooja D, Singh MK, Chauhan AS) Drug Dev Ind Pharm 2015 Feb;41(2):232-8 55 Citations |
| 2 | Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. (Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J) J Thorac Oncol 2014 May;9(5):702-9 51 Citations |
| 1 | Heat shock protein-mediated protection against Cisplatin-induced hair cell death. (Baker TG, Roy S, Brandon CS, Kramarenko IK, Francis SP, Taleb M, Marshall KM, Schwendener R, Lee FS, Cunningham LL) J Assoc Res Otolaryngol 2015 Feb;16(1):67-80 37 Citations |
| 1 | Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. (Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT) J Clin Oncol 2014 Dec 01;32(34):3858-66 427 Citations |
| 4 | Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. (Santana-Davila R, Devisetty K, Szabo A, Sparapani R, Arce-Lara C, Gore EM, Moran A, Williams CD, Kelley MJ, Whittle J) J Clin Oncol 2015 Feb 20;33(6):567-74 121 Citations |
| 1 | NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. (Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W Jr, Gaffney DK) Cancer 2015 Jul 01;121(13):2156-63 51 Citations |
| 1 | A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. (Di Trapani E, Sanchez-Salas R, Gandaglia G, Rocchini L, Moschini M, Lizee D, Carneiro A, Sivaraman A, Barret E, Rozet F, Galiano M, Bennamoun M, Colombo R, Suardi N, Briganti A, Montorsi F, Cathelineau X) World J Urol 2016 Feb;34(2):207-13 17 Citations |
| 1 | Sensorineural Hearing Loss after Combined Intensity Modulated Radiation Therapy and Cisplatin-Based Chemotherapy for Nasopharyngeal Carcinoma. (Wang J, Chen YY, Tai A, Chen XL, Huang SM, Yang C, Bao Y, Li NW, Deng XW, Zhao C, Chen M, Li XA) Transl Oncol 2015 Dec;8(6):456-62 31 Citations |
| 1 | Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. (O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF) Clin Genitourin Cancer 2016 Dec;14(6):511-517 5 Citations |
| 1 | Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. (Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, Kim ES) PLoS One 2016;11(5):e0155503 7 Citations |
| 1 | Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. (Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB) J Clin Oncol 2016 Aug 10;34(23):2712-20 245 Citations |
| 1 | Updated 4-Year Results for NRG Oncology/RTOG 0921: A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer (A.N. Viswanathan
K. Winter
B.E. Miller
Y. Xiao
A. Jhingran
L. Portelance
W.R. Bosch
U. Matulonis
N. Horowitz
R. Mannel
L. Souhami
B.A. Erickson
W. Small Jr.
D.K. Gaffney) International Journal of Radiation Oncology, Biology, Physics ORAL SCIENTIFIC SESSION| VOLUME 96, ISSUE 2, SUPPLEMENT , S49-S50, OCTOBER 01, 2016 |
| 1 | Patient-Reported Outcomes (PROs) in NRG Oncology/RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Esophageal Cancer Treated Without Surgery (L.A. Kachnic
J. Moughan
M. Suntharalingam
D.H. Ilson
A.A. Konski
W. Burrows
C. Anker
V. Bar Ad
H.V. Thakrar
J.P. Hayes
E.M. Gore
V.S. Kavadi
R.U. Komaki
A. Raben
J.K. Giguere
J. Pollock
J.S. Greenberger
G.M. Videtic
K.S. Roof
D. Watkins Bruner
) International Journal of Radiation Oncology, Biology, Physics ORAL SCIENTIFIC SESSION| VOLUME 96, ISSUE 2, SUPPLEMENT , S31, OCTOBER 01, 2016 |
| 1 | Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. (Xiao C, Zhang Q, Nguyen-Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Winquist E, Jones CU, Robinson W, Raben D, Le QT, Bruner D) Int J Radiat Oncol Biol Phys 2017 Mar 15;97(4):667-677 35 Citations |
| 1 | Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. (Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB, Platinum Study Group) J Clin Oncol 2017 Apr 10;35(11):1211-1222 92 Citations |
| 1 | Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer (McDonald ME, Mattson J, Hill E) Gynecologic Oncology Reports 1 May 2017;20:103-104 7 Citations |
| 2 | Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck. (Awan MJ, Nedzi L, Wang D, Tumati V, Sumer B, Xie XJ, Smith I, Truelson J, Hughes R, Myers LL, Lavertu P, Wong S, Yao M) Ann Oncol 2018 Apr 01;29(4):998-1003 23 Citations |
| 1 | Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. (Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB, Platinum Study Group) J Clin Oncol 2018 May 20;36(15):1505-1512 110 Citations |
| 1 | Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer. (Yavas G, Yavas C, Sen E, Oner I, Celik C, Ata O) Int J Gynecol Cancer 2019 Jan;29(1):42-47 31 Citations |
| 1 | Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer. (Shahjehan F, Kamatham S, Ritter A, Kasi PM) Clin Case Rep 2019 Sep;7(9):1729-1734 2 Citations |
| 1 | Relationship of cisplatin-related adverse health outcomes with disability and unemployment among testicular cancer survivors (Kerns SL, Fung C, Fossa SD, Dinh PC, Monahan P, Sesso HD, Frisina RD, Feldman DR, Hamilton RJ, Vaughn D, Martin N, Huddart R, Kollmannsberger C, Sahasrabudhe D, Ardeshir-Rouhani-Fard S, Einhorn L, Travis LB) Jnci Cancer Spectrum 2020;4(4) 16 Citations |
| 1 | Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma. (Lander M, Abedin Y, Gabrilovich S, Marcus JZ) Gynecol Oncol Rep 2020 May;32:100552 4 Citations |
| 1 | Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors. (Kerns SL, Fung C, Fossa SD, Dinh PC Jr, Monahan P, Sesso HD, Frisina RD, Feldman DR, Hamilton RJ, Vaughn D, Martin N, Huddart R, Kollmannsberger C, Sahasrabudhe D, Ardeshir-Rouhani-Fard S, Einhorn L, Travis LB) JNCI Cancer Spectr 2020 Aug;4(4):pkaa022 |
| 1 | miRNAs Modulate the Dichotomy of Cisplatin Resistance or Sensitivity in Breast Cancer: An Update of Therapeutic Implications. (Safi A, Bastami M, Delghir S, Ilkhani K, Seif F, Alivand MR) Anticancer Agents Med Chem 2021;21(9):1069-1081 9 Citations |
| 1 | DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity (Hama T, Nagesh PKB, Chowdhury P, Moore BM, Yallapu MM, Regner KR, Park F) Jci Insight 22 November 2021;6(22) 10 Citations |
| 1 | DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity. (Hama T, Nagesh PK, Chowdhury P, Moore BM 2nd, Yallapu MM, Regner KR, Park F) JCI Insight 2021 Nov 22;6(22) 10 Citations |
| 1 | Avasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients. (Mapuskar KA, Vasquez Martinez G, Pulliam CF, Petronek MS, Steinbach EJ, Monga V, Furqan M, Jetton JG, Saunders DP, Pearce A, Davidson S, Pitre L, Dunlap NE, Fairbanks R, Lee CM, Mott SL, Bodeker KL, Cl H, Buatti JM, Anderson CM, Beardsley RA, Holmlund JT, Zepeda-Orozco D, Spitz DR, Allen BG) Redox Biol 2023 Apr;60:102599 16 Citations |
| 1 | Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice. (Kaur K, Chen PC, Ko MW, Mei A, Senjor E, Malarkannan S, Kos J, Jewett A) Front Immunol 2023;14:1132807 27 Citations |
| 1 | Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer (Jameson GS, Hosein PJ, Pierce E, Kamgar M, Gordon MS, Snyder C, Roe DJ, Wertheim BC, Davey M, Barrett MT, Von Hoff DD, Borazanci E) Cancer Medicine June 2024;13(12) 3 Citations |
| 1 | Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery. (Kachnic LA, Winter K, Suntharalingam M, Ilson D, Konski A, Lloyd S, McAvoy SA, Lad T, Olowokure OG, Samson P, Gore EM, Meyer JE, Videtic GMM, Clump DA, Raben A, Kayaleh O, Barker J Jr, Haddock MG, Hopkins JO, Bruner DW) Qual Life Res 2024 Oct;33(10):2833-2844 2 Citations |
| 1 | Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. (Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, Chang SS, Jordan RC, Liu T, Truong MT, Winquist EW, Takiar V, Wise-Draper T, Robbins JR, Rodriguez CP, Awan MJ, Beadle BM, Henson C, Narayan S, Spencer SA, Powell S, Dunlap N, Sacco AG, Hu KS, Park HS, Bauman JE, Harris J, Yom SS, Le QT) Lancet Oncol 2024 Dec;25(12):1576-1588 53 Citations |
| 1 | Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer. (Kerns SL, Dinh PC Jr, Monahan PO, Stump T, Fung C, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Huddart R, Kollmannsberger C, Martin NE, Nevel K, Kincaid J, Einhorn LH, Travis LB) J Natl Cancer Inst 2025 Sep 01;117(9):1797-1808 3 Citations |
| 1 | Mannitol Administration and the Risk for Cisplatin-Induced Nephrotoxicity (Kathryn E.K. Berlin, DO, FAAP; Aniko Szabo, PhD; Bhavna Bhasin-Chhabra, MBBS, MD; Ariel Nelson, MD, MS; Thomas Giever, DO, MBA; Amanda G. Pawlenty, PharmD, BCOP; Deepak Kilari, MD; Stuart J. Wong, MD) Mannitol Administration and the Risk for Cisplatin-Induced Nephrotoxicity |
| 1 | Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology RTOG 9911. (Langer CJ, Harris J, Horwitz EM, Kies M, Ad VB, Wong SJ, Caudell JJ, Zeitzer KL, Spencer SA, Zhang Q, Yom SS, Le QT) Int J Radiat Oncol Biol Phys 2026 Jan 01;124(1):50-60 2 Citations |
| 1 | Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapy. (Kerns SL, Dinh PC Jr, Monahan PO, Fung C, Sesso HD, Feldman DR, Hamilton RJ, Pierazio P, Huddart R, Kollmannsberger C, Martin NE, Einhorn LH, Travis LB) J Natl Cancer Inst 2026 Feb 12 |
© 2026 Clinical & Translational Science Institute